resmetirom
Compuesto químico
Resmetirom, sold under the brand name Rezdiffra, is a medication used to treat a form of fatty liver disease. Specifically it is used in the treatment of non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH) (formerly known as nonalcoholic steatohepatitis NASH).
Nº Q27288071 ★
Común · Saberes
resmetirom
Compuesto químico
Resmetirom, sold under the brand name Rezdiffra, is a medication used to treat a form of fatty liver disease. Specifically it is used in the treatment of non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH) (formerly known as nonalcoholic steatohepatitis NASH).
Último precio
—
Precio mínimo
—
Mediana 7 d
—
Ventas 30 d
0
Rango 30 d
—
En circulación
0
Cotización
mediana
mín – máx
ventas
Sin ventas en el periodo
Ver tabla
| Fecha | mediana | Mín | Máx | ventas |
|---|
Historial de ventas
- Última venta
- —
- Media 30 d
- —
- Mínimo 30 d
- —
- Máximo 30 d
- —
- Ventas 7 d
- 0
- Ventas 30 d
- 0
Aún no hay ventas.
Ventas anónimas: sin comprador ni vendedor. Las cifras solo cuentan ventas entre jugadores.
En Wikipedia
Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.
Resmetirom, sold under the brand name Rezdiffra, is a medication used to treat a form of fatty liver disease. Specifically it is used in the treatment of non-cirrhotic metabolic dysfunction associated steatohepatitis (MASH) (formerly known as nonalcoholic steatohepatitis NASH). It is structurally similar to the thyroid hormone triiodothyronine and acts as an agonist of the thyroid hormone receptor beta (NR1A2). The most common side effects include diarrhea and nausea. Resmetirom was approved for medical use in the US in March 2024, and in the European Union in August 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
Texto: Wikipedia en inglés, CC BY-SA 4.0. · Imagen: User:Innerstream (Public domain) ·
